Patient Preferences for Fixed vs. Continuous Therapies in CLL - Dr .Brian Koffman ASH 2023

The greatest patient-reported treatment preference for those with chronic lymphocytic leukemia (CLL) was for therapies that offered a 90% progression-free survival (PFS) at two years over those who offered a 70% PFS.

Given equal efficacy, patients with CLL prefer fixed-duration over treat-to-progression therapies.

Dr. Brian Koffman from the CLL Society and colleagues presented the results at the American Society for Hematology (ASH) Annual Meeting 2023.

__________________________________________________________________________________________